Ns Hari Narayana Moorthy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8282466/publications.pdf

Version: 2024-02-01

44 papers	893 citations	430874 18 h-index	477307 29 g-index
44 all docs	44 docs citations	44 times ranked	1428 citing authors

#	Article	IF	Citations
1	Protein-Ligand Docking in the New Millennium â€“ A Retrospective of 10 Years in the Field. Current Medicinal Chemistry, 2013, 20, 2296-2314.	2.4	197
2	Human CDC2-Like Kinase 1 (CLK1): A Novel Target for Alzheimerâ€™s Disease. Current Drug Targets, 2014, 15, 539-550.	2.1	73
3	Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis. Current Medicinal Chemistry, 2013, 20, 4888-4923.	2.4	44
4	Synthesis, Biological Evaluation and In Silico Metabolic and Toxicity Prediction of Some Flavanone Derivatives. Chemical and Pharmaceutical Bulletin, 2006, 54, 1384-1390.	1.3	35
5	Synthesis, Cytotoxic Evaluation and In Silico Pharmacokinetic Prediction of Some Benzo[a]Phenazine-5-sulfonic acid Derivatives. Medicinal Chemistry, 2009, 5, 549-557.	1.5	32
6	QSAR analysis of 2-benzoxazolyl hydrazone derivatives for anticancer activity and its possible target prediction. Medicinal Chemistry Research, 2012, 21, 133-144.	2.4	29
7	2-(4-Aminophenyl) Benzothiazole: A Potent and Selective Pharmacophore with Novel Mechanistic Action Towards Various Tumour Cell Lines. Mini-Reviews in Medicinal Chemistry, 2006, 6, 633-637.	2.4	28
8	Structural analysis of Î±-glucosidase inhibitors by validated QSAR models using topological and hydrophobicity based descriptors. Chemometrics and Intelligent Laboratory Systems, 2011, 109, 101-112.	3.5	28
9	Iodineâ€Catalyzed, Oneâ€Pot, Solidâ€Phase Synthesis of Benzothiazole Derivatives. Synthetic Communications, 2007, 37, 4327-4329.	2.1	26
10	Development of Ribonucleotide Reductase Inhibitors: A Review on Structure Activity Relationships. Mini-Reviews in Medicinal Chemistry, 2013, 13, 1862-1872.	2.4	26
11	Design, synthesis and biological evaluation of some novel 3-cinnamoyl-4-hydroxy-2H-chromen-2-ones as antimalarial agents. Medicinal Chemistry Research, 2012, 21, 1780-1784.	2.4	25
12	QSAR modelling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P_VSA and pharmacophore feature descriptors. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 6089-6094.	2.2	21
13	3D QSAR of Aminophenyl Benzamide Derivatives as Histone Deacetylase Inhibitors. Medicinal Chemistry, 2010, 6, 277-285.	1.5	21
14	Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds. SAR and QSAR in Environmental Research, 2012, 23, 521-536.	2.2	20
15	Design, synthesis and molecular modelling studies of novel 3-acetamido-4-methyl benzoic acid derivatives as inhibitors of protein tyrosine phosphatase 1B. European Journal of Medicinal Chemistry, 2013, 70, 469-476.	5.5	20
16	Design, synthesis, cytotoxic evaluation, and QSAR study of some 6H-indolo[2,3-b]quinoxaline derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2010, 25, 394-405.	5.2	19
17	Structural feature study of benzofuran derivatives as farnesyltransferase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2011, 26, 777-791.	5.2	19
18	QSAR analysis of some 5-amino-2-mercapto-1,3,4-thiadiazole based inhibitors of matrix metalloproteinases and bacterial collagenase. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3847-3854.	2.2	18

#	Article	IF	Citations
19	hERG binding feature analysis of structurally diverse compounds by QSAR and fragmental analysis. RSC Advances, 2011, 1, 1126.	3.6	18
20	In Silicoâ€"Based Structural Analysis of Arylthiophene Derivatives for FTase Inhibitory Activity, hERG, and Other Toxic Effects. Journal of Biomolecular Screening, 2011, 16, 1037-1046.	2.6	16
21	A new approach for PEGylation of dendrimers. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4279-4281.	2.2	15
22	Ligand based analysis on HMG-CoA reductase inhibitors. Chemometrics and Intelligent Laboratory Systems, 2015, 140, 102-116.	3.5	15
23	Topological, hydrophobicity, and other descriptors on Î±-glucosidase inhibition: a QSAR study on xanthone derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 2011, 26, 755-766.	5.2	14
24	QSAR study of substituted 2-pyridinyl guanidines as selective urokinase-type plasminogen activator (uPA) inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 6-13.	5.2	13
25	Prediction of the relationship between the structural features of andrographolide derivatives and Î±-glucosidase inhibitory activity: A quantitative structure-activity relationship (QSAR) Study. Journal of Enzyme Inhibition and Medicinal Chemistry, 2011, 26, 78-87.	5.2	13
26	COMPARATIVE STUDY OF FORCED DEGRADATION BEHAVIOR OF PRASUGREL BY UPLC AND HPLC AND THE DEVELOPMENT OF VALIDATED STABILITY INDICATING ASSAY METHOD. Journal of Liquid Chromatography and Related Technologies, 2011, 34, 1870-1884.	1.0	10
27	QSAR and pharmacophore analysis of thiosemicarbazone derivatives as ribonucleotide reductase inhibitors. Medicinal Chemistry Research, 2012, 21, 739-746.	2.4	10
28	Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 317-324.	5.2	10
29	Structural Analysis of 2-Piperidin-4-yl-Actamide Derivatives for hERG Blocking and MCH R1 Antagonistic Activities. Current Drug Discovery Technologies, 2012, 9, 25-38.	1.2	9
30	A Validated UPLC Method Used for the Determination of Trandolapril and its Degradation Products as per ICH Guidelines. Current Pharmaceutical Analysis, 2011, 7, 182-188.	0.6	8
31	Design, synthesis and biological evaluation of novel arylidine-malononitrile derivatives as non-carboxylic inhibitors of protein tyrosine phosphatase 1B. Medicinal Chemistry Research, 2013, 22, 5344-5348.	2.4	8
32	Virtual screening and QSAR study of some pyrrolidine derivatives as Î±-mannosidase inhibitors for binding feature analysis. Bioorganic and Medicinal Chemistry, 2012, 20, 6945-6959.	3.0	7
33	Structural analysis of structurally diverse Î±-glucosidase inhibitors for active site feature analysis. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 649-657.	5.2	7
34	Binding mode prediction and identification of new lead compounds from natural products as renin and angiotensin converting enzyme inhibitors. RSC Advances, 2014, 4, 19550-19568.	3.6	7
35	Synthesis, in silico metabolic and toxicity prediction of some novel imidazolinones derivatives as potent anticonvulsant agents. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 201-207.	5.2	6
36	Synthesis, Characterization, Biological Evaluation and Docking of Coumarin Coupled Thiazolidinedione Derivatives and its Bioisosteres as PPARÎ³ Agonists. Medicinal Chemistry, 2012, 8, 834-845.	1.5	5

#	Article	IF	Citations
37	Atom based 3D-QSAR study of 1,4-benzodiazepine-2-ones as potent anti-trypanosomal agents and its validation. Medicinal Chemistry Research, 2014, 23, 765-774.	2.4	4
38	Quantitative Structure Activity Relationship Studies of Piperazinyl Phenylalanine Derivatives as VLA-4/VCAM-1 Inhibitors. Medicinal Chemistry, 2009, 5, 446-454.	1.5	3
39	Modeling VEGFR kinase inhibition of aminopyrazolopyridine urea derivatives using topological and physicochemical descriptors: a quantitative structure activity analysis study. Medicinal Chemistry Research, 2012, 21, 3958-3964.	2.4	3
40	Analysis of surface area features of structurally diverse molecules for Bcr/Abl kinase inhibitory activity and antiproliferative activity. Medicinal Chemistry Research, 2014, 23, 2622-2632.	2.4	3
41	Multi-algorithm based machine learning and structural pattern studies for hERG ion channel blockers mediated cardiotoxicity prediction. Chemometrics and Intelligent Laboratory Systems, 2021, 208, 104213.	3.5	3
42	QSAR Study on Hetaryl Imidazoles: A Novel Dual Inhibitor of VEGF Receptors I and II. Medicinal Chemistry, 2010, 6, 24-29.	1.5	2
43	In silico Based Structural Analysis of Some Piperidine Analogs as Farnesyltransferase Inhibitors. Medicinal Chemistry, 2012, 8, 853-864.	1.5	2
44	Quantitative Structure Activity Analysis of 2-Alkoxydihydrocinnamates as PPARα /γ Dual Agonist. Medicinal Chemistry, 2008, 4, 273-277.	1.5	1